Illuminare Biotechnologies Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

Illuminare Biotechnologies General Information

Description

Developer of intra-operative nerve visualization systems designed to reduce the risk of nerve damage. The company's candidate binds specifically to myelin and illuminates to make nerves, fat, muscles, and blood vessels more visible, helping surgeons with more improved visibility during operations.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Primary Office
  • 327 Saint Marks Avenue
  • Brooklyn, NY 11238
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Illuminare Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 01-Jan-2021 00.000 Completed Pre-Clinical Trials
2. Early Stage VC 17-Dec-2018 Cancelled Stealth
1. Early Stage VC (Series A) 18-Aug-2017 $2.37M $2.37M 000.00 Completed Stealth
To view Illuminare Biotechnologies’s complete valuation and funding history, request access »

Illuminare Biotechnologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Illuminare Biotechnologies’s complete cap table history, request access »

Illuminare Biotechnologies Executive Team (4)

Name Title Board Seat Contact Info
Walter Greenblatt Chairman & Acting Chief Executive Officer
Kathleen Deardorff Acting Chief Operating Officer
Roger Morgan MD Chief Medical Officer
Ezra Angrist Acting Chief Financial Officer
To view Illuminare Biotechnologies’s complete executive team members history, request access »

Illuminare Biotechnologies Board Members (5)

Name Representing Role Since
Oliver Curme Self Board Member 000 0000
Robert Graifman Self Board Member 000 0000
Shay Grinfield Illuminare Biotechnologies Board Member 000 0000
Walter Greenblatt Illuminare Biotechnologies Chairman & Acting Chief Executive Officer 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Illuminare Biotechnologies Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Endo Investors Venture Capital Minority 000 0000 000000 0
General Electric Corporation Minority 000 0000 000000 0
Memorial Sloan Kettering Cancer Center Corporation Minority 000 0000 000000 0
To view Illuminare Biotechnologies’s complete investors history, request access »